Connor, Clark & Lunn Investment Management Ltd.

Position in CRL — Charles River Laboratories International, Inc.

CIK 1596800 VANCOUVER, A1

Position in CRL

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$9,413,325

-$17,348,113 QoQ

Shares Held

54,570

-59.3% QoQ

Ownership

0.114%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $189,818,037 across 16 Diagnostics & Research names.

#	Ticker	Company	Shares	Value (USD)
1	MEDP	Medpace Holdings, Inc.	110,353	$58,441,845
2	GH	Guardant Health, Inc.	215,395	$32,315,711
3	DHR	Danaher Corp /De/	114,010	$21,716,624
4	TMO	Thermo Fisher Scientific Inc.	36,269	$18,183,825
5	NEO	Neogenomics Inc	802,597	$11,709,889
6	RVTY	Revvity, Inc.	87,145	$9,695,752
7	MYGN	Myriad Genetics Inc	1,407,860	$8,038,880
8	CSTL	Castle Biosciences Inc	331,727	$7,911,688

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$9,413,325	54,570	-59.3%	Shares	Sole	2026-05-11
2025-12-31	$26,761,438	134,156	-25.7%	Shares	Sole	2026-02-10
2025-09-30	$28,251,043	180,564	-5.6%	Shares	Sole	2025-11-13
2025-06-30	$29,021,093	191,268	+670.0%	Shares	Sole	2025-08-07
2025-03-31	$3,738,766	24,839	+45.9%	Shares	Sole	2025-05-12
2023-12-31	$4,025,182	17,027	+0.6%	Shares	Sole	2024-02-09
2022-06-30	$3,621,014	16,923	-35.0%	Shares	Sole	2022-08-05
2022-03-31	$7,392,591	26,033	-42.2%	Shares	Sole	2022-05-12
2021-12-31	$16,962,258	45,019	+74.6%	Shares	Sole	2022-02-10
2021-09-30	$10,641,108	25,786	+251.3%	Shares	Sole	2021-11-12
2021-06-30	$2,715,212	7,340	-12.6%	Shares	Sole	2021-08-12
2020-03-31	$1,059,659	8,396	—	Shares	Sole	2020-05-13
No filing history on record for this holder in this stock.